U.S. Transportation Stock News

Kymera Therapeutics stock has delivered a very strong 404.9% return over the past three years, yet the company currently screens as expensive on Simply Wall St’s valuation checks, raising the question of how much of the recent clinical progress is already reflected in the price. A roughly 4x gain over three years suggests investors have rapidly repriced Kymera Therapeutics on expectations that its drug pipeline can create meaningful long term value. Faster than expected enrollment in the...

Simply Good Foods stock has rebounded in the short term, but the longer history is much harsher, with the shares down around 63% over the past three years while broader valuation checks suggest the stock does not currently screen as a clear bargain. The roughly 63% share price decline over three years points to investors reassessing what they are willing to pay for Simply Good Foods. Future growth in branded snacking and effective cost control can support the valuation, but any slowdown in...

On 27 June 2026, Cirrus Logic, Inc. was added to the Russell 1000 Defensive Index and the Russell 1000 Value-Defensive Index, marking its inclusion in two prominent benchmarks focused on resilience and value characteristics. This dual index addition may broaden Cirrus Logic’s institutional investor base, as index-linked funds and portfolio managers adjust holdings to align with the updated Russell compositions. Next, we’ll explore how Cirrus Logic’s inclusion in the Russell 1000 Defensive...

Jade Biosciences stock reacts to index reshuffle and board appointment Jade Biosciences (JBIO) just saw its index profile tilt toward growth benchmarks, coinciding with the appointment of seasoned immunology executive Mark Eisner, M.D., M.P.H., to the board of directors. See our latest analysis for Jade Biosciences. At a share price of $21.51, Jade Biosciences has given investors a 30 day share price return of 21.18% and a 1 year total shareholder return of 93.09%. This reflects momentum...

Revolution Medicines (NasdaqGS:RVMD) reported Phase 1/2 trial data for its RAS(ON) inhibitor combinations in metastatic pancreatic cancer. The investigational therapies, zoldonrasib with standard chemotherapy or daraxonrasib, showed strong antitumor activity and manageable safety in patients with RAS G12D metastatic pancreatic ductal adenocarcinoma. The results support ongoing and planned Phase 3 trials in both first line and previously treated settings, in an indication that currently lacks...

Artificial intelligence is moving beyond chatbots, and the latest funding surge for AMI Labs and its JEPA project is a reminder that investors are now paying close attention to AI systems that can reason about the real world. That shift in research focus and capital flows can ripple through established companies that already reference AI or robotics in their business descriptions. This article looks at 3 stocks from the Artificial Intelligence Innovation Leaders screener that appear closely...

FMC stock is coming off a difficult stretch, with the share price well below past levels, yet both the intrinsic value estimate using a Discounted Cash Flow (DCF) approach and the market multiples currently point to the shares trading at a discount to underlying value. FMC shareholders have seen the stock decline 87.6% over the past 3 years, which puts the current valuation front and center for anyone considering whether the reset has gone too far. Recent steps to raise cash, including a...

In late June 2026, Excelerate Energy, Inc. (NYSE:EE) was added to several Russell growth and small‑cap benchmarks, including the Russell 2000 Growth and Russell 3000 Growth indices. These index inclusions expand Excelerate Energy’s presence in widely tracked benchmarks, potentially increasing its visibility among institutional investors and passive index funds. We’ll now examine how Excelerate Energy’s broad addition to Russell growth indices could shape its existing LNG-focused investment...

Why National Bank Holdings Stock Is Back on Investors’ Radar National Bank Holdings (NBHC) stock has been drawing fresh attention after a recent period of strong share price performance, prompting investors to reassess the trade off between its returns and business quality. Over the past six months NBHC has risen 16.2%, outpacing the S&P 500 by 10.1%. That move comes alongside a 2.83% dividend yield and mixed signals in the company’s longer term growth profile. See our latest analysis for...

Serve Robotics stock has fallen 46.7% year to date, yet on the basic valuation checks it still does not screen as a clear bargain, with a low overall value score and an apparently supportive read from market multiples pulling in different directions for investors trying to price the story. The share price is down 46.7% year to date, which puts the current valuation under pressure to show that the business case can justify even today's lower level. The recent move to extend its AI powered...

In late June 2026, Grocery Outlet Holding Corp. was removed from both the Russell 2000 Value-Defensive Index and the Russell 2000 Defensive Index, reflecting changes in how the company is classified within these benchmarks. This double index removal can influence how certain institutional investors and index-linked funds treat the stock, potentially altering trading activity and perceptions of Grocery Outlet’s defensive profile. With Grocery Outlet now excluded from key Russell 2000...

In late June 2026, short seller Culper Research disclosed a short position in Tarsus Pharmaceuticals and alleged concerns over the company’s Medicare copay practices, while shareholders at the June 25, 2026 annual meeting re-elected Class III directors, approved executive pay on an advisory basis, and ratified Ernst & Young LLP as auditor. A series of new equity awards to non-employee directors, vesting over time and tied to continued board service, underscores Tarsus’s emphasis on aligning...

Dow (NYSE:DOW) has entered a long term partnership with Univar Solutions to distribute its Decarbia low carbon product portfolio. The agreement focuses on supplying lower carbon materials to sectors including beauty and personal care, food, and pharmaceuticals. The collaboration is aimed at supporting customers that are working toward supply chain decarbonization and tighter ESG requirements. For investors watching Dow, this move is closely aligned with its chemicals and materials business,...

ADT launched ADT Blu, a new app controlled, self installed security camera system targeting the DIY home security market. The product focuses on flexible, app driven monitoring for customers who prefer to set up and manage their own smart home security. ADT Blu expands the company’s offerings beyond its traditional professional installation and long term contract model. ADT (NYSE:ADT) is adding ADT Blu to its product lineup at a time when the stock trades at $6.83 and recent performance has...

U.S. and Chinese authorities are investigating suspected large-scale insider trading tied to Futu Holdings (NasdaqGM:FUTU) accounts. The activity reportedly occurred just before China announced a regulatory crackdown on cross-border brokerages. The U.S. Justice Department and SEC are leading the probe, alleging anonymous traders may have made significant profits using advance knowledge of the crackdown. Court orders have frozen certain accounts at Futu Holdings as part of the ongoing...

Zimmer Biomet Holdings has fallen about 40.9% over the past five years, yet on current checks the stock still screens as undervalued, which raises the question of whether sentiment has swung harder than the fundamentals justify. The share price decline of roughly 40.9% over five years signals that investors have been cautious about Zimmer Biomet Holdings despite its established position in medical devices. The planned acquisition of Pacira BioSciences' iovera device can support expectations...

CONMED stock sits at about US$33.83 after a very weak five year run, yet its valuation checks now point to a company that screens cheap on several measures. For investors, that contrast between long term share price weakness and a stronger valuation profile is the core question around CONMED today. CONMED shares have fallen about 74% over the past five years, which means the current price is being set after a prolonged period of weak returns. The key potential support for the valuation is...

Franklin Covey (FC) has just posted its Q3 2026 numbers, with revenue of $67.8 million and basic EPS of $0.27, setting the tone for how investors assess its recent profitability. The company has seen revenue move from $67.1 million in Q3 2025 to $67.8 million in Q3 2026, while basic EPS shifted from a loss of $0.11 to a profit of $0.27 over the same period. This frames a clear earnings swing alongside a relatively stable top line. For investors, the latest quarter highlights how margins are...

Public Service Enterprise Group is preparing its grid and customers for an upcoming extreme heatwave expected to bring sustained high temperatures. The company is focusing on infrastructure readiness, safety guidance and outreach to vulnerable customers ahead of the heat event. These efforts highlight Public Service Enterprise Group's approach to resiliency and community support during climate related stress on the power system. Public Service Enterprise Group, traded as NYSE:PEG, is...

Political risk is no longer just background noise for investors, it is starting to shape which stocks could face pressure and which might see fresh demand as trust in US legal and regulatory institutions comes under strain. With senior legal figures warning about retribution prosecutions and signs of stress inside the Department of Justice, companies closely tied to enforcement, oversight, and risk management are squarely in focus. This article breaks down three stocks exposed to the latest...

Why this patent and board news matters for Xeris Biopharma Holdings stock Xeris Biopharma Holdings (XERS) has drawn fresh attention after securing a USPTO notice of allowance for a Keveyis related patent that may extend protection to 2039, alongside several board and leadership changes. For investors, the patent development is important because it relates directly to a marketed therapy, Keveyis, and the company has indicated it plans to seek inclusion of this intellectual property in the...

FactSet Research Systems (FDS) opened its Q3 2026 scorecard with revenue of US$622.9 million and basic EPS of US$3.51, set against trailing twelve month revenue of about US$2.4 billion and EPS of US$15.27 that frame the current run rate. Over recent quarters the company has seen revenue progress from US$570.7 million in Q2 2025 to US$596.9 million in Q4 2025 and US$622.9 million in Q3 2026. Quarterly EPS has moved from US$3.81 to US$4.07 and then US$3.51, which feeds directly into a trailing...

With inflation trends, interest rate expectations and growth signals all pulling in different directions, many investors are looking for stocks where management has meaningful skin in the game and sees room for further expansion. The Fast Growing Stocks With High Insider Ownership screener focuses on companies with stronger growth potential, supported by positive views from both analysts and insiders who are closely tied to future outcomes. This article highlights 3 stocks from that screener...

Earlier in 2026, Barclays initiated coverage on Zurn Elkay Water Solutions with an overweight rating and a US$59.00 price objective, while the company also declared a US$0.11 per share quarterly cash dividend payable in June 2026. Together, the upbeat Barclays initiation and steady dividend signal growing institutional interest in Zurn Elkay’s role in non-residential construction and water management trends. Next, we’ll examine how Barclays’ positive initiation, highlighting non-residential...